Deep Track Capital, LP Protagonist Therapeutics, Inc Call Options Transaction History
Deep Track Capital, LP
- $2.86 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PTGX
# of Institutions
293Shares Held
60.7MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$270 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$255 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$253 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$189 Million0.0% of portfolio
-
State Street Corp Boston, MA2.71MShares$120 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.17B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...